The market for drugs that target rare diseases is expected to rival big pharma blockbusters in the coming decades.
Advertisement
The Nutshell
Daily News Roundup
Most Recent
Proposals from researchers receiving more than $1 million a year in NIH funding will be carefully picked over to avoid overlap with ongoing research.
A polar bear in a German zoo dies after contracting a virus normally found in zebras.
A former manager at Genentech claims the company bypassed ethical and clinical guidelines in order to rush a promising drug through clinical trials.
Patent expirations of one HIV drugs will make the disease cheaper—but also more cumbersome—to treat.
The rise in the amount of federal money requested through research grants is due to a rise in the overall number of applicants.
Australian trout are susceptible to skin cancer, according to a new study—the first evidence that wild fish can be afflicted by the disease.
The National Institutes of Health will fund 17 projects developing lab-on-a-chip applications to improve drug screening.
An approved cancer therapeutic makes hiding HIV susceptible to antiviral therapy.
The first full computer model of a single-celled organism mimics the bacterium’s behaviors and paves the way to more complete disease models.
Subjects
- cell & molecular biology
- clinical trials
- culture
- disease/medicine
- ecology
- evolution
- funding
- genetics & genomics
- NIH
- policy
Sub Categories
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Advertisement
Current Issue
